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emergency room visits, and quality-adjusted life-years.RESULTS: PP-LAI was dom-
inant. It cost €10,169/patient; outcomes included 330.1 days in remission, 25% were
hospitalized, 12% visited emergency rooms and 0.845 QALY. OLZ-LAI costs were
€11,589; patients experienced 326.8 remission days and 0.844 QALY; 27% were hos-
pitalized and 14% visited emergency rooms. RIS-LAI costs were €12,091; patients
experienced 323.8 remission days and 0.836 QALY; 30% were hospitalized and 14%
visited emergency rooms. For all products, costs were approximately 35% due to
drugs, 48% hospitalization, and the remainder due to medical care. The analysis
was robust against most variations in input values; adherence rates were sensitive.
PP-LAI was dominant over OLZ-LAI and RIS-LAI in 50% and 73% of simulations,
respectively. CONCLUSIONS: In Finland, PP-LAI dominated the other LAIs as it was
associated with a lower cost and better clinical outcomes.
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OBJECTIVES: To perform economic evaluation of paliperidone palmitate suspen-
sion for injection (PPI) compared to risperidone long acting injection (RLAI) for the
treatment of schizophrenia from Russian health care system point of view.
METHODS: Direct medical costs of treating schizophrenia with PPI and RLAI for 1
year were calculated in an Excel model. The model was based on simulation of rate
of relapse taking into account the expected adherence to treatment. The key pa-
rameters of the model were derived from the systematic review of the RCTs results,
e-STAR observational study (local data for Russia) and expert panel opinions. Ad-
herence simulation was based on the assumption that reduced number of injec-
tions will decrease number of patients giving up treatment and thus decrease
probability of relapse. Direct costs of treatment included hospitalization for the
relapse, outpatient care visits, and the cost of RLAI and PPI Sensitivity analysis to
the variations of key parameters was made. RESULTS: Analysis of the results of
RCTs has not shown superiority of RLAI-based treatment efficacy or safety over
PPI-based treatment. The only possible advantage is increased adherence rate due
to reduced number of injections per month. If adherence increases from 75.7% to
82.3% the costs of medical care in a hypothetical cohort of patients with schizo-
phrenia is less for PPI 6.36 bln USD vs 6.45 bln USD in case of RLAI (per year). Thus
difference in costs in a hypothetical cohort of patients with schizophrenia is 87,881
USD, or 87.88 USD per patient. Variation in the level of non-adherence to treatment
did not influence the results but the economic advantage of PPI disappears when its
price increases by1.5% from baseline. CONCLUSIONS: PPI may constitute a cost-
saving treatment option for patients with schizophrenia if its price is no more than
6.62 USD per mg.
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OBJECTIVES: To assess the cost-effectiveness of escitalopram as first line treat-
ment of MDD in Belgium. METHODS: The model structure was based on a decision
tree developed by the Swedish Dental and Pharmaceutical Benefits Agency (TLV).
Comparators included citalopram, fluoxetine, paroxetine, sertraline, duloxetine,
venlafaxine and mirtazapine. In the model, patients not achieving remission or
relapsing on the assessed treatment moved to a second therapeutic step (titration,
switch, add-on or transfer to a specialist). In case of failure in the second step or
following a suicide attempt, patients were assumed to be referred to secondary
care. The time horizon was one year and the analysis was conducted from the
NIHDI (national health insurance) and societal perspectives. Remission rates were
obtained from a network meta-analysis published by the TLV and other model
parameters were derived from the published literature and experts’ opinion. To
reflect local practices, a recent Belgian survey of 97 GPs (general practitioners) on
the management of MDD was used. The effect of uncertainty in model parameters
was estimated through scenario analyses and a probabilistic sensitivity analysis
(PSA). RESULTS: In the base case analysis, escitalopram was identified as the opti-
mal strategy: it dominated all other treatments except venlafaxine from the NIHDI
perspective, against which it was cost-effective with an incremental cost-effective-
ness ratio of €6,351 per quality-adjusted-life-year (QALY). Due to the high cost of
absenteeism, escitalopram dominated all other strategies from the societal per-
spective. At a threshold of €30,000 per QALYs from the NIHDI perspective, the PSA
showed that, in comparison to the other drugs, escitalopram had a probability
between 61% (vs. venlafaxine) and 100% (vs fluoxetine) to be identified as the op-
timal strategy. CONCLUSIONS: Escitalopram was identified as the optimal strategy
from the NIHDI and societal perspectives. This study investigated ways to present
sensitivity analyses while comparing multiple strategies.
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OBJECTIVES: To estimate cost-effectiveness of different (7 drugs) peroral atypi-
cal antipsychotics (AAP) vs haloperidol (H) for the treatment of schizophrenia.
METHODS: Cost-effectiveness analysis of AAP compared to H for schizophrenia
treatment was performed. A mathematical model based on simulation of treat-
ment outcomes in hypothetical cohort of patients was developed. Key parame-
ters of the model were determined using systematic review of the RCTs results
(improvement in clinical and functional status as measured by the PANSS and
CGI, frequency of relapse, adverse events), e-STAR observational study (local
data for Russia), epidemiological data and expert panel opinions. For each op-
tion direct costs of treatment were considered: hospitalization and outpatient
care, and the cost of medications for AAP- and H-based treatment. ICER (cost of
a day without exacerbation of the disease) for each AAP was calculated vs H.
RESULTS: According to published trials the treatment of schizophrenia in the
AAP-based therapy was associated with a significant improvement in PANSS
and CGI, decreased rate of relapse and adverse events compared to H-based
treatment. Analysis of the results of RCTs has not shown superiority of any
certain drug inside the AAP group. In case of application of AAP-based therapy
hospitalization rate decreases by 38% compared to H-based treatment but the
total cost of treatment remains lower for H. Depending on the drug ICERaap for
AAP vs H varies from 4,202 USD to 18,157 USD per day without exacerbation of
the disease. In group AAP paliperidone has the lowest ICER vs H - 4202 USD.
CONCLUSIONS: Results of the study suggest that AAP-are more efficacious com-
pared to H, the total cost of treatment remains lower for H. In-group AAP paliperi-
done is more cost-effective.
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OBJECTIVES: Depression has a lifetime prevalence of 10–25% among women and
5–12% among men. Selective serotonin reuptake inhibitors (SSRIs) are the most
used and the most cost effective treatment in long-term MDD. Since the introduc-
tion of generic SSRIs the costs of the branded drug have been questioned. The
objective of this study is to analyze the Cost-effectiveness of the most prescribed
SSRIs: sertraline, paroxetine, citalopram, that lost their patent, and escitalopram
that is still covered by a patent. METHODS: A decision analytic model was adapted
from TLV (Dental and Pharmaceutical Benefits Board, Sweden) in order to reflect
the current clinical practice in depression helped by a panel of Psychiatrists and
Health economists. Perspective used was the Lombardy Region Health Service and
the Time horizon was 12 months. Several scenario simulations, one way Sensitivity
analyses and Monte Carlo simulations have been performed in order to test the
robustness of the model. RESULTS: Base case scenario showed an ICER of escita-
lopram vs. sertraline of € 4.395. All the tests showed that citalopram and paroxetine
are dominated. One way Sensitivity analyses and tests were performed resulting in
ICER variation from € 135 to € 18.000, nevertheless Monte Carlo simulations have
shown an ICER stabilized at the mean value of around 4.000 euro confirming the
base case scenario. CONCLUSIONS: ICER represents the additional cost due to a
new technology related to its additional benefits. ICER has to be compared with a
meaningful threshold value under which a technology may be considered cost-
effective. Many agencies have studied this threshold. PBAC (Australia) propose €
25K, NICE (UK) propose € 35K. Comparing our base case scenario and also the ICER
ranges that came from the Sensitivity analyses (One way and multivariate) with
these thresholds escitalopram should be accepted as a cost-effective treatment for
MDD.
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OBJECTIVES: Several studies have demonstrated that Risperidone Long-Acting
Injectable (RLAI) reduces psychotic relapses, hospitalization and resources used
among schizophrenic patients with poor adherence to oral medication. How-
ever, the magnitude of such reductions depends upon the baseline relapse rate.
This study is aimed at identifying the thresholds of relapse risk at which RLAI is
cost-effective, compared to Oral Olanzapine (OO), Oral Quetiapine (OQ) and
Haloperidol Decanoate (HD). METHODS: A Markov model was developed to sim-
ulate the natural history of schizophrenia for patients who have poor adherence
and high risk of relapse with oral medication. The strategies compared were
starting treatment with RLAI, OO, OQ or HD. Relapse probabilities, adherence
levels, side effects and treatment switching were derived from long-term obser-
vational data. Resource use and costs were obtained from Mexican public insti-
tutions. Patients transit through different health states in the model on a
monthly basis over a 10-year time horizon. Incremental cost and effectiveness
outcomes were discounted at 3% annually. RESULTS: In patients with Baseline
Annual Relapse Rate (BARR) equal or greater than 72.5%, RLAI is the most effec-
tive and less costly treatment (cost-saving) if effectiveness is measured in terms
of QALYs or relapses averted. In this case, RLAI produces 0.27 (5.13-5.4) addi-
tional discounted QALYs and avoids 3.97 relapses, compared to OO. According
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to the WHO Commission on Macroeconomics and Health, RLAI is highly cost-
effective (1xGDP per-capita/QALY gained) in patients with a BARR between
63% and 72.5% and cost-effective (3xGDP per-capita /QALY gained) in patients
with a BARR between 35% and 63%. CONCLUSIONS: In all published naturalistic
studies comparing RLAI with oral medication, where the selection of patients to
receive RLAI is left to the physicians, the BARR is greater than 0.71, which
suggest that using RLAI in Mexico with similar criteria of patient selection
would result in a cost-saving strategy.
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OBJECTIVES: Evaluate the effectiveness of quetiapine extended release (XR) versus
quetiapine immediate release (IR) in Mexican Schizophrenic patients from a gov-
ernmental perspective.METHODS: Effective measurements were taken from Meu-
lien=s, et al, 2010 meta-analysis and a systematic review done for this analysis.
Cost-effectiveness and a cost utility analysis were done. Effectiveness measure-
ments were: percentage of patients adherent to treatment, reporting adverse
events (AEs) and with relapse. Disease-specific utility values assigned to each of the
6 schizophrenia disease states, based in the possible combinations of adherence
levels (full, partial, or nonadherence) and the relapse results, have been estimated
by Furiak, 2009 using the Positive and Negative Syndrome Scale, and expert opin-
ion. Costs considered are direct medical care, drug, AEs and relapse treatment.
Analysis used a governmental perspective (Mexican Institute of Social Services
costs), (published May 2012). A Markov model was performed considering a one
year horizon with 3 month cycles simulating schizophrenic Mexican population
with the proposed treatment alternatives. Finally a univariated probabilistic sen-
sitivity analysis was done to validate consistency in the model. RESULTS: The use
of quetiapine XR resulted in more adherent patients with 0.17846 compared with
0.05630 for quetiapine IR; less AEs reported with 0.13716 compared with 0.05462
respectively. In the cost-utility analysis quetiapine XR had an average QALYs of
0.14620 compared to quetiapine IR QALYS of 0.1256. Quetiapine XR generated a cost
saving of USD 508.52 (conversion rate: USD13.14 MxPesos. Average 2012).
CONCLUSIONS: Based on the data from the review and meta-analysis, quetiapine
XR had a similar efficacy and tolerability profile than quetiapine IR but with better
results in effectiveness measures (adherence, adverse events and QALYs). It re-
duces direct treatment costs in Mexican public Institutions with a positive estimate
impact. Based on these, quetiapine XR is a dominant alternative, more effective
and with less costs tan quetiapine IR.
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OBJECTIVES: Schizophrenia is marked by a characteristic interference pattern of
various psychological areas such as perception, ego-function, affectivity and
psychomotricity. Thus, the objective of this economic analysis is the evaluation
of the cost saving potential through the use of Paliperidone Palmitate compared
to Risperidon Depot. METHODS: The pharmaeconomic evaluation was per-
formed using a cost-minimization analysis, in which the above mentioned ther-
apeutic alternatives with equal effectiveness and efficiency are compared based
on the net costs to determine the most cost-effective alternative. The equiva-
lence of the comparators was confirmed in the study of Pandina et al. (2011).
Clinical data derived from this 13-week, double-blind head-to-head study. The
time horizon is 2-years. RESULTS: From the perspective of the health insurance,
the average costs of the therapy algorithm of Paliperidone Palmitate amount to
€5,024.02 for the first year of treatment. A patient treated with Risperidone
Depot is causing costs of €4,750.63. If the patient is treated with Paliperidone
Palmitate as a first-line treatment in the following year, costs of €4,222.32 arise.
In case of a treatment with Risperidone Depot costs amount to €4,594.76 EUR. If
a patient is treated with Paliperidone Palmitate throughout the period under
observation, the discounted total costs for 2-years amount to €9,247.02. Treat-
ment with Risperidone Depot is causing costs of €9,345.40, resulting in a cost
advantage for Paliperidone Palmitate compared to Risperidone Depot of €98.37
for the period of two years. Observing the costs over a time horizon of five years,
a treatment with Paliperidone Palmitate is causing costs in the amount of
20,008.15 EUR. For the same period, a treatment with Risperidone Depot is caus-
ing costs of €20,851.47. CONCLUSIONS: In the treatment of schizophrenia, Pali-
peridone Palmitate is a cost-effective alternative therapy. Additionally, the sen-
sitivity analysis shows that the analysis is, with the exception of doctor
consultations, robust.
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OBJECTIVES: To evaluate the cost-effectiveness of genetic screening for Apolipo-
protein 4 (APOE 4) allele in combination with preventive donepezil treatment in
comparison to the standard of care for Amnestic Mild Cognitive Impairment (AMCI)
patients in Canada.METHODS:We performed a cost-effectiveness analysis using a
Markov model with a societal perspective and a time horizon of 30 years. For each
strategy, we calculated quality-adjusted life years (QALYs) using utilities from the
literature. Costs were also based on the literature, and when appropriate, Ontario
sources. One-way and probabilistic sensitivity analyses were performed. Expected
value of perfect information (EVPI) was conducted to explore the value of future
research. RESULTS: The base case results in our exploratory study suggest com-
bined genetic testing and preventive donepezil treatment resulted in a gain of 0.011
QALYs and an incremental cost of CAD $394 compared to standard of care. The
incremental cost-effectiveness ratio (ICER) for the base case was $35,161 per QALY.
The ICER was sensitive to the effectiveness of donepezil treatment in delaying
progression to AD, and the costs of AD and donepezil. EVPI analysis showed that
additional information on these parameters would be of value. CONCLUSIONS:
Using presently available clinical evidence, this exploratory study illustrates ge-
netic testing combined with preventive donepezil treatment for AMCI patients may
be economically attractive. Since our results were based on a secondary post-hoc
analysis, our study alone is insufficient to warrant recommending APOE genotyp-
ing in AMCI patients. Future research on the effectiveness of preventive donepezil
as a targeted therapy is recommended.
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OBJECTIVES: This evaluation aimed to assess the cost-effectiveness of paliperi-
done palmitate in different lines of therapy for schizophrenia patients compared to
the current patient pathway. METHODS: A Markov model was developed that ex-
amined the use of five different treatment sequences, each involving paliperidone
palmitate at different points in the sequence. Variations in treatment sequences
were assessed to examine their impact on the model’s findings, and were com-
pared with a comparator treatment sequence reflecting current practice. The
model simulated the three main schizophrenic health states of remission, minor
relapse and major relapse. Adherence with medication is also taken into consider-
ation due to its impact on resource use, quality of life and the probability of relapse.
The model adopted a timeline of five years and used a Spanish health care provider
perspective. Drug costs are assumed to be ex factory. RESULTS: The difference in
costs associated with introduction of paliperidone palmitate at different moments
of patient course ranges from an additional €260 when used as a fourth-line ther-
apy to a reduction of €2,217 (i.e. cost saving) when directly used as a second-line
therapy after a course of daily risperidone treatment. Cost savings arose due to
reduced rates of relapse. All five treatment sequences resulted in an increase in
QALYs, ranging from 0.043 QALYs for fourth-line therapy to 0.124 QALYs per pa-
tient for second-line treatment. Second-line treatment was dominant to all other
treatment sequences. Probabilistic sensitivity analysis suggests that the probabil-
ity of paliperidone palmitate being cost-effective as a second-line therapy is 96.8%
at both €30,000 and €45,000 thresholds. One year analysis gave similar results, with
palmitate paliperidone as second-line therapy also dominant to all other treatment
sequences. CONCLUSIONS: Paliperidone palmitate used as second line after a
course of daily risperidone treatment is the dominant alternative when compared
to the other scenarios.
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OBJECTIVES: Schizophrenia is affecting the young adults and amounts to ap-
proximately 80,000 people in Austria, suffering at least one time during their life
from a psychotic episode, which meet the DSM-IV criteria of schizophrenia.
Patients with schizophrenia are at high risk of relapse due to non-adherence of
oral antipsychotic medication. The purpose of this analysis was to estimate the
cost-effectiveness of switching to Paliperidone palmitate after first-line oral
Olanzapine or Risperidone versus an oral treatment algorithm. METHODS: We
developed a Cost-Utility-Model to simulate the consequences of two treatment
algorithms; one with Paliperidone palmitate after treatment failure or stop of
Olanzapine or Risperidone versus a second with oral medication (starting with
Risperidone, Olanzapine, Quetiapine, Haloperidol, Ziprasidone and last-line
Clozapine, followed by no-treatment) over a 5-years horizon. Markov-modeling
techniques were used to estimate incidence of relapse, hospitalization, treat-
ment switch and death. Monte-Carlo simulation accounted for uncertainty. The
model includes eleven health-states. Probabilities were derived from clinical
studies. Direct medical costs from published sources were used and expressed
in 2011 Euro from the payer’s perspective. QALYs and costs were discounted at
5% p.a. RESULTS: Over a 5-year timeframe, costs associated with the use of
Paliperidone palmitate amounts to 28,328.94€ and 3.62 QALYs. Costs associated
with the oral treatment-path are 26,338.23€ and 3.20 QALYs. The incremental-
costs amount to 1,990.71€ per patient and the incremental-cost per QALY gained
was 4,739.79€. The Markov-cohort description shows that 55% of patients who
receive Paliperidone palmitate are still on treatment after 5-years and 24% have
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